

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: minimal size of the groups n = 5

EQA round: T01/22 - SARS-CoV-2 antibodies (study)

Deadline: 28.01.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(515) SARS-CoV-2 antibodies IgG (S)					67							44	35	80%
--- Samples and groups ---	[-]													
Sample A		1170	1000	88	67							44	37	84%
(1) BAU/mL; (1) Abbott		570	43	7,5	10	0	CVPG	570	33	25%	427	713	10	
(1) BAU/mL; (140) Test-Line		1110	160	14	7	0	CVPG	1110	150	25%	832	1390	7	
(1) BAU/mL; (164) DiaSorin		1780	360	20	8	0	CVPG	1780	280	25%	1330	2230	8	
(2) AU/mL; (1) Abbott		3930	360	9,1	11	0	CVPG	3930	260	25%	2940	4920	11	
(2) AU/mL; (164) DiaSorin		432	220	50	8	0	CVPG	432	160	25%	324	540	8	
Other					23	1							0	
														4x 1/12, 1x 1/14, 4x 1/87, 2x 1/162, 1x 1/179, 3x 2/12, 1x 3/1, 2x 3/60, 1x 3/140, 1x 4/162, 2x 99/87, 1x 99/149
Sample B		645	590	92	67							44	39	89%
(1) BAU/mL; (1) Abbott		272	11	4,0	10	0	CVPG	272	8,5	25%	204	340	10	
(1) BAU/mL; (140) Test-Line		847	230	27	7	0	CVPG	847	220	25%	635	1060	7	
(1) BAU/mL; (164) DiaSorin		694	50	7,2	8	0	CVPG	694	38	25%	520	868	8	
(2) AU/mL; (1) Abbott		1880	170	8,8	11	0	CVPG	1880	120	25%	1410	2350	11	
(2) AU/mL; (164) DiaSorin		232	62	27	8	0	CVPG	232	47	25%	174	290	8	
Other					23	1							0	
														4x 1/12, 1x 1/14, 4x 1/87, 2x 1/162, 1x 1/179, 3x 2/12, 1x 3/1, 2x 3/60, 1x 3/140, 1x 4/162, 2x 99/87, 1x 99/149
(516) SARS-CoV-2 antibodies IgG (NC)					17							5	0	0,00
--- Samples and groups ---	[-]													
Sample A		25,9	26	100	17							5	0	0,00
(3) U/mL; (140) Test-Line		28,2	15	53	5	0	CVPG	28,2	42	25%	21,1	35,3	5	
Other					12	1							0	
														1x 1/14, 2x 1/140, 1x 1/999, 1x 2/1, 1x 2/999, 3x 4/1, 3x 4/87
Sample B		20,5	19	92	17							5	4	80%
(3) U/mL; (140) Test-Line		26,4	1,5	5,6	5	0	CVPG	26,4	4,2	25%	19,8	33	5	
Other					12	1							0	
														1x 1/14, 2x 1/140, 1x 1/999, 1x 2/1, 1x 2/999, 3x 4/1, 3x 4/87
(517) SARS-CoV-2 total Ig (S)					26							21	15	71%
--- Samples and groups ---	[-]													
Sample A		3080	760	25	26							21	15	71%
(1) BAU/mL; (60) Roche		3450	660	19	5	1	CVPG	3450	650	25%	2580	4320	5	
(3) U/mL; (60) Roche		2930	670	23	16	2	CVPG	2930	440	25%	2190	3670	16	
Other					5	2							0	
														1x 1/0, 1x 1/162, 1x 1/164, 2x 2/1
Sample B		1610	200	12	26							21	16	76%
(1) BAU/mL; (60) Roche		1490	170	11	5	1	CVPG	1490	170	25%	1110	1870	5	
(3) U/mL; (60) Roche		1600	160	10	16	2	CVPG	1600	110	25%	1200	2000	16	
Other					5	3							0	
														1x 1/0, 1x 1/162, 1x 1/164, 2x 2/1
(518) SARS-CoV-2 total Ig (NC)					7							6	6	100%
--- Samples and groups ---	[-]													
Sample A		20,3	3,1	15	7							6	6	100%
(4) positivity index; (60) Roche		20,4	2,9	14	6	0	CVPG	20,4	4,0	25%	15,3	25,5	6	
Other					1	0							0	
														1x 4/999
Sample B		39,0	5,3	14	7							6	6	100%
(4) positivity index; (60) Roche		41,2	2,1	5,0	6	0	CVPG	41,2	2,9	25%	30,9	51,5	6	
Other					1	0							0	
														1x 4/999
(519) SARS-CoV-2 antibodies IgM					29							18	17	94%
--- Samples and groups ---	[-]													
Sample A		0,455	0,10	22	29							18	17	94%
(4) positivity index; (1) Abbott		0,515	0,022	4,3	9	0	CVPG	0,515	0,028	25%	0,386	0,644	9	
(4) positivity index; (164) DiaSorin		0,452	0,056	12	9	0	CVPG	0,452	0,070	25%	0,339	0,565	9	
Other					11	0							0	
														1x 2/1, 1x 2/999, 1x 3/140, 2x 4/12, 2x 4/87, 3x 4/140, 1x 4/999
Sample B		1,25	0,54	43	29							18	18	100%
(4) positivity index; (1) Abbott		1,71	0,059	3,5	9	0	CVPG	1,71	0,073	25%	1,28	2,14	9	
(4) positivity index; (164) DiaSorin		1,20	0,15	12	9	0	CVPG	1,2	0,18	25%	0,9	1,5	9	
Other					11	0							0	
														1x 2/1, 1x 2/999, 1x 3/140, 2x 4/12, 2x 4/87, 3x 4/140, 1x 4/999
(520) SARS-CoV-2 antibodies IgA					15							7	3	43%
--- Samples and groups ---	[-]													
Sample A		9,88	9,3	95	15							7	5	71%

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: minimal size of the groups n = 5

EQA round: T01/22 - SARS-CoV-2 antibodies (study)

Deadline: 28.01.2022

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel}
							AV	U _{AV}	D _{max}	LL	UL				
(520) SARS-CoV-2 antibodies IgA															
Samples and groups [-]															
15															
7 3 43%															
Sample A															
(4) positivity index; (87) Euroimmun															
9,88 9,3 95 15															
6,77 1,2 18 7 1 CVPG 6,77 1,7 25% 5,07 8,47 7 5 71%															
Other															
8 0															
1x 1/140, 3x 3/140, 3x 4/140, 1x 4/999															
Sample B															
(4) positivity index; (87) Euroimmun															
15,2 17 110 15															
8,34 2,5 30 7 1 CVPG 8,34 3,4 25% 6,25 10,5 7 4 57%															
Other															
8 0															
1x 1/140, 3x 3/140, 3x 4/140, 1x 4/999															
(521) SARS-CoV-2 neutralizing antibodies															
Samples and groups [-]															
6															
0															
Sample A															
Other															
767 990 130 6															
6 0															
1x 1/999, 1x 3/12, 1x 3/36, 1x 3/60, 1x 99/87, 1x 99/166															
Sample B															
Other															
635 800 130 6															
6 0															
1x 1/999, 1x 3/12, 1x 3/36, 1x 3/60, 1x 99/87, 1x 99/166															

st_kn_p

End of report

Printed: 18.02.2022